Medically reviewed by: Jayden Lee, PharmD, EMBA Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison specializing in pharmacogenomics and clinical product development, with more than 10 years of professional experience in clinical pharmacy, academia, and research
ATTAIN-1 Phase 3 (Orforglipron for Obesity)
When the glycemic level outcome was investigated through a subgroup analysis consisting of 100% diabetics, the heterogeneity level dropped to zero
Cross-contamination risk jumps when a used needle moves from one vial to another
Safety check Peptides can vary by legal status, compounding pathway, purity testing, patient history, and interaction risk
Exp Mol Med 53 , 115124 (2021)